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Warfarin, an oral vitamin K antagonist, is used to prevent arterial and venous thromboembolism in
patients suffering from a multitude of diseases. In 2004, 31 million warfarin prescriptions were
dispensed in the United States. Warfarin inhibits the activation of the vitamin K–dependent clotting
factors (Factors II, VII, IX, and X) and regulatory proteins (proteins C, S, and Z). It is one of the leading
drugs implicated in emergency room visits for adverse drug reactions. Annually the frequency of
bleeding complicationsassociatedwith overanticoagulation is 15% to 20%, with fatal bleeds measuring
as high as 1% to 3%. The most effective method of warfarin reversal involves the use of Four Factor
Prothrombin Complex Concentrate (PCC), which is widely used throughout Europe but is unavailable
in the United States. The current therapies available to emergency room physicians in the United
States are fresh frozen plasma, recombinant Factor VIIa (rFVIIa), Factor Eight Inhibitory Bypassing
Activity, or Three Factor PCC concomitantly administered with vitamin K. We review the advantages
and disadvantages of these therapies and recommend Three Factor PCC with small doses of rFVIIa
and with vitamin K in life-threatening situations if Four Factor PCC is unavailable. [West J Emerg Med.
2011;12(4):386–392.]
INTRODUCTION
In 2002 it was estimated that more than 3 million people,
or 1.6% of the US population, were taking an oral vitamin K
antagonist (VKA) such as warfarin. In men and women who
were 65 years old or older the percentages were as high as 8%
and 4%, respectively.
1 VKAs are routinely used for the primary
and secondary prevention of arterial and venous
thromboembolism in patientswith prosthetic heart valves, atrial
ﬁbrillation, peripheral arterial disease, antiphospholipid
syndrome, and recurrent myocardial or cerebral infarction.
2–4
Warfarin is the most commonly prescribed VKA worldwide
and belongs to a group of drugs known as coumarins. It works
by inhibiting the C1 subunit of the enzyme vitamin K epoxide
reductase (VKOR), which is necessary for the activation of the
vitamin K–dependent coagulation factors (Factors II, VII, IX,
and X [Figure 1]) and regulatory proteins (proteins C, S, and
Z).
5
The challenge with coumarin therapy is balancing the
beneﬁt of anticoagulation versus the inherent risk of bleeding
due to the functional deﬁciency of the coagulation factors. The
frequency of warfarin-induced bleeding is 15% to 20% per
year, with life-threatening or fatal bleeding rates as high as 1%
to 3% per year.
6–9 As the US population ages, the number of
patients taking warfarin, as well as the number of patients
presenting to the emergency room as a result of complications,
will likely increase. Emergency room physicians should be
aware of current and future therapies for rapid reversal of
anticoagulant therapy.
VITAMIN K ANTAGONIST
Warfarin therapy can be problematic as a result of its
narrow therapeutic index, highly variable dosage requirements
among patients, and signiﬁcant drug, dietary, and disease
interactions.
5 Bleeding can result from gross abnormalities,
such as hemophilia A or B, or from more subtle single
nucleotide polymorphic mutations, such as those found in
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reductase, or in Factor IX propetide. These often-undiagnosed,
subtle changes can increase the likelihood of a hemorrhagic
complication associated with warfarin therapy.
CYP2C9 is a microsomal enzyme partially responsible for
coumarin breakdown. Mutated CYP2C9 results in reduced
coumarin metabolism and, subsequently, a longer half-life,
thereby increasing the risk of hemorrhage with a standard dose
of warfarin.
5 VKOR is responsible for reducing vitamin K to its
active form, which is necessary for the activation of thevitamin
K–dependent clotting factors. Mutated VKOR leads to
insufﬁcient levels of reduced vitamin K and, consequently,
vitamin K–dependent clotting factors.
5 The addition of VKA
therapy would compound this deﬁciency and increase the
patient’s risk of hemorrhaging. In addition, a point mutation in
the Factor IX propeptide results in extremely low levels of
Factor IX during warfarin treatment, which in turn leads to an
increased risk of bleeding.
5,10
In addition to pharmacogenetic considerations there are
also important drug, dietary, and disease interactions to be
aware of with coumarin therapy. While it is outside the scope of
this review to list every drug or supplement that may interact
with coumarins, Ansell et al
5 provide a comprehensive list in
their 2008 article. As a result of their routine use in emergency
departments, it is important to note that aspirin and a variety of
antibiotics (among them levoﬂoxacin, azithromycin,
trimethoprim/sulfamethoxazole, and second- and third-
generation cephalosporins) augment or potentiate the coumarin
response, while barbiturates, rifampin, and cholestyramine
increase clearance or reduce absorption.
5,11 Diet can also play a
key role in coumarin therapy—too much vitamin K intake can
reduce the response to VKA therapy, while fat malabsorption or
reduced vitamin K intake can potentiate the coumarin response.
Hepatic dysfunction and hypermetabolic states, such as fever,
also potentiate or increase the responsiveness to VKA therapy.
5
Assessment of anticoagulation due to VKA therapy is
typically done using the international normalized ratio (INR),
which is the ratio of a patient’s prothrombin time compared to a
standard prothrombin time. The prothrombin time measures 3
of the 4 vitamin K–dependent coagulation factors (Factors II,
VII, and X).
5 A normal INR is between 0.8 and 1.2. The INR
for patients on VKA therapy varies according to the underlying
condition but is typically between 2.0 and 3.5.
2,4 An INR of less
than 2.0 is associated with increased risk of thromboembolic
events, while an INR of greater than 4.0 is associated with
increased risk of bleeding.
12
VKA therapy can be difﬁcult to control and needs to be
closely tracked in order to ensure patient safety. In a 2002
study,
12 the medical records of 1,020 patients (12,897 INR
values) receiving warfarin were retrospectively analyzed to
determine how much time was spent either above or below the
target INR. The authors reported a total of 3,810 (29.5%) INR
values that were either above 4.0 or below 2.0; of these, 3,484
(27%) were considered to be outside of the target range. A
separate study
13 looked at INR values among patients with
atrial ﬁbrillation and found that only 43.7% of the INRs were
within the target range. A study by Van Leeuwen et al
14 found
that patients who spent more time outside of their target INR
range had a 2.6-fold increased risk of bleeding.
ADVERSE EFFECTS OF VKAs
In 1 year, up to 6.5% of patients on anticoagulant therapy
will experience a major bleeding event affecting their soft
tissue, gastrointestinal tract, or urinary tract. Approximately 1%
of patients will develop a fatal bleed, often an intracranial
hemorrhage (ICH).
8,15,16 It was estimated in 2007 that 8,000 to
10,000 cases of coumarin-associated ICH occurred in the
United States.
17 In a cohort study
18 of 11,526 patients with
nonvalvular atrial ﬁbrillation it was reported that those patients
receiving VKA therapy were 1.97 times more likely to suffer
from ICH as those not on coumarin therapy.
A prospective, multicenter study
21 involving 2,745 ﬁrst-
time patients was conducted to assess bleeding complications
associated with VKA therapy. A total of 153 bleeding events
Figure 1. Coagulation cascade. * indicates vitamin K–dependent coagulation factors.
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hemorrhages, and 125 minor hemorrhages) during the course
of the study. The authors found 3 variables leading to an
increased risk of hemorrhage: age (greater than 70 years), the
ﬁrst 90 days of treatment, and intensity of anticoagulation (INR
greater than 4.5). Patients over 70 years of age or those in the
ﬁrst 90 days of treatment were 1.75 times as likely to suffer a
bleeding complication as those under age 70 or those outside of
the 90-day window. Those patients with an INR of 4.5 or
greater were 7.91 times as likely experience to bleeding as
those with an INR under 4.5.
19 Other studies
20–23 have reported
history of bleeding, chronic alcohol abuse, disease, and
concurrent use of other drugs as additional factors that increase
the risk of hemorrhage.
TREATMENT OPTIONS FOR REVERSAL
OF OVERANTICOAGULATION
There are several methods with which to reverse the
anticoagulant effect of warfarin, including the omission of a
dose of warfarin, administration of an oral or intravenous dose
of vitamin K, use of fresh frozen plasma (FFP), Three- or Four-
Factor Prothrombin Complex Concentrate (3F PCC, 4F PCC),
recombinant Factor VIIa (rFVIIa), or the use of Factor Eight
Inhibitor Bypassing Activity (FEIBA) (Figure 2). The clinical
situation (absence of bleeding, major bleed, etc) must be
evaluated in addition to the patient’s INR to determine the
appropriate method to use to reverse the anticoagulation. The
American College of Chest Physicians has released a set of
guidelines for the reversal of anticoagulation therapy (Table).
5
The simplest method of reversal is the withholding of 1 or
more doses of the VKA. Although the coagulopathy begins to
correct within 24 to 36 hours, it will not fully correct for 3 to 5
days; therefore, this method is only appropriate for an
asymptomatic patient with an elevated INR or a very minor
bleed.
24,25 For a patient who is at a high risk of bleeding, oral
vitamin K must be administered in concert with the omission of
a dose of warfarin.
5,26
Since the mechanism of coumarin action is competitive
inhibition of VKOR with a subsequent decrease in the activity
of the vitamin K–dependent coagulation factors, vitamin K
itself can be used as a treatment. Administration of vitamin K
overpowers the anticoagulation system and turns on the
endogenous activation of the coagulation factors. Vitamin K
can be administered subcutaneously, orally, or intravenously.
Subcutaneous vitamin K is not signiﬁcantly different from
placebo in terms of correcting aberrant INRs.
27 Although both
oral and intravenously administered vitamin K are effective at
correcting supratherapeutic INRs at 24 hours posttreatment,
intravenous vitamin K can correct the INR much sooner, in as
few as 4 to 6 hours.
5,28 While intravenous vitamin K has
repeatedly been proven effective, it is not without risks; it has
been associated with severe anaphylactic reactions. For this
reason, the American College of Chest Physicians, the
American Heart Association, the American College of
Cardiology, the Australasian Society of Thrombosis and
Haemostasis, and the American Society of Hematology have
suggested that the use of intravenous vitamin K be limited to
life-threatening situations.
3,5,29,30
There are 2 other interventions available to be used in
patients with a major hemorrhage (Figure 2). FFP was the most
commonly used agent for the replacement of coagulation
factors in the United States as of 2008.
29 It contains vitamin K–
dependent coagulation Factors II, VII, and X; however, it lacks
sufﬁcient levels of factor IX. As of 2008 the American College
of Chest Physicians, the Australasian Society of Thrombosis
and Haemostasis, and the British Committee for Standards in
Haematology have all released guidelines for the use of FFP
with supratherapeutic INR. While these recommendations are
similar, there are noticeable differences. The Australasian
guidelines recommend considering the use of 150 to 300 mL of
FFP with an INR of greater than 9.0 even without bleeding. In
contrast, both the British and American guidelines do not
mention the use of FFP until major bleeding is present. With
major bleeding, all 3 guidelines recommend FFP use at 15 cc/
Figure 2. Vitamin K–dependent factors that are replenished with the use of recombinant Factor VIIa, fresh frozen plasma, Three-Factor
Prothrombin Complex Concentrate (PCC), Four-Factor PCC, and Factor Eight Inhibitor Bypass Activity.
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guidelines speciﬁcally recommend PCC over FFP in cases of
life-threatening bleeding.
31
There are a signiﬁcant number of concerns about the use of
FFP in coumarin-associated overanticoagulation. As a blood
product prepared from either whole blood or plasmapheresis,
FFP must be ABO matched to the patient before transfusion
can begin. Another issue contributing to the speed with which
FFP can be administered is the fact that it requires time to thaw
(since it is stored at 48C) before it can be given to the patient.
32
A retrospective study by Lee et al
33 found that a median time of
6.5 hours was needed to infuse 5 U of FFP to patients who
suffered from warfarin-induced ICH. As with all blood
products, FFP carries a risk, however slight, of pathogen
transmission; it is recommended that patients receiving large or
repeated doses of FFP be vaccinated for both hepatitis A and
B.
32 Of particular concern is the varying levels of coagulation
factors seen in FFP, which may result in a partial or insufﬁcient
reversal of INR.
28 Perhaps most worrying for the use of FFP in
overanticoagulated patients is the sheer volume that is often
required to reverse the coagulation defect: it is not uncommon
to rapidly transfuse 2 to 4 L (approximately 8–16 U) in patients
with greatly elevated INRs.
17 Rapid transfusion of large
volumes can lead to cardiogenic lung edema, and transfusion of
FFP speciﬁcally has been associated with a noncardiogenic
lung edema known as transfusion-related acute lung injury
(TRALI).
34,35 While immunogenic TRALI is rare (1 per 5,000
transfusions), it requires mechanical ventilation in 70% of cases
and is fatal in 6% to 9% of cases.
34 Because of these limitations,
FFP is recommended for use only in situations where other,
more effective therapeutics are not readily available.
4,28,30,36,37
rFVIIa and FEIBA are newer therapies for warfarin
reversal in bleeding patients. rFVIIa activatesFactor X to Factor
Xa, allowing the formation of thrombi.
38 Several small
studies
39–43 have shown that rFVIIa can quickly correct
supratherapeutic INRs with doses ranging from 10 to 90 lg/kg.
However, the majority of the patients in these studies also
received FFP and vitamin K; therefore, it is unclear if rFVIIa
alone can be effective in acute warfarin reversal. Additionally,
its high cost for an average patient ($5,542 for an average dose
versus $2,205 for the same patient on PCC) and short half-life
of 2.5 to 3 hours make it a less favorable candidate with which
to treat warfarin-induced coagulopathy.
44 The incidence of
thrombotic adverse events associated with rFVIIa is rare, 24.5
per 10
5 infusions, with an elevated risk for cerebrovascular
thrombosis.
45
FEIBA is an activated PCC. It contains activated Factor
VII and small amounts of activated Factors II, IX, and X.
46 A
study by Wo ´jcik et al
47 found that 56 of 72 nonhemophiliac
patients (77.8%) with life-threatening bleeds associated with
warfarin survived after treatment with FEIBA concomitantly
administered with 10 mg of vitamin K. The INR of patients
receiving FEIBA normalized 12 times faster than did that of
those receiving FFP. Like rFVIIa, FEIBA contains the activated
form of Factor VII, but it is not as costly.
47 A
pharmacovigilance study
45 found the incidence of thrombotic
adverse events associated with FEIBA to be 8.24 per 10
5
infusions. The overwhelming majority of research on FEIBA
has been conducted with hemophiliac patients; therefore, more
studies need to be done with patients on warfarin therapy.
While 4F PCC contains all the vitamin K–dependent
coagulation factors and is widely used in European countries, it
has not been approved by the Food and Drug Administration
for use in the United States. 3F PCC, which lacks adequate
levels of Factor VII in relation to Factors II, IX and X, is in
limited use in the United States. A recent study
48 showed that
3F PCC administered alone cannot adequately lower the
supratherapeutic INR levels to less than 3 in 50% of patient as a
result of its low levels of Factor VII. Only after the
administration of FFP in concert with 3F PCC were INR levels
sufﬁciently corrected.
The most effective product available for the rapid reversal
of overanticoagulation is 4F PCC.
16 3F PCC and 4F PCC have
a number of advantages over FFP. While FFP must be thawed
before use, PCCs are stored as a lyophilized powder at room
temperature and are reconstituted in sterile water immediately
prior to use, which means they can be administered much more
quickly than FFP.
28 Additionally, PCCs typically undergo 2
viral inactivation steps and are further puriﬁed and pooled,
making them safer than FFP in terms of the transmission of
pathogens, especially HIVand hepatitis B and C. This
puriﬁcation process also obviates the need for ABO
matching.
4,28,29,49,50 Finally, PCCs offer known quantities of the
vitamin K–dependent coagulation factors in small volumes,
which substantially reduces the risks associated with large-
volume infusions of FFP. The concentration of the coagulation
Table. The American College of Chest Physicians guideline for the reversal of anticoagulation therapy (8th ed.).
INR Recommendation
,5 Hold 1 dose or lower dose of warfarin
5.0–,9 Add 1–2.5 mg of oral vitamin K
.9 (no bleeding) Hold warfarin and give 2.5–5.0 mg of oral vitamin K
Any major bleeding Hold warfarin and give 10 mg intravenous vitamin K in addition to fresh frozen plasma,
Prothrombin Complex Concentrate, or recombinant Factor VIIa
INR, international normalized ratio.
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it necessary to administer higher volumes of FFP (2–4 L of FFP
vs 20–50 U/kg of PCC) to have the same effect.
51 In a
retrospective study
37 of 17 patients with anticoagulant-related
ICH treated with either FFP or 4F PCC, it was discovered that
INRs of patients treated with 4F PCC were reversed 4 to 5 times
more rapidly than those of patients treated with FFP. Similarly,
in a prospective study
52 of 41 patients requiring rapid reversal
of VKA-associated overanticoagulation, 28 of 29 patients
treated with 4F PCC showed a complete correction of the INR
within 15 minutes (mean INR of 1.3), while 0 of 12 patients
treated with FFP corrected within this time frame (mean INR of
2.3). A number of other studies
15,24,49,50,53–58 have conﬁrmed
the efﬁcacy of PCCs in the rapid reversal of elevated INRs.
The main concerns associated with PCCs are the risks of
thromboembolism. In a meta-analysis of 14 studies with 460
patients, only 7 thromboembolic complications were observed.
All of these complications occurred in only 3 of the 14 studies.
Additionally, 4 of the7 thrombotic eventswere ‘‘likely linked to
underlying patient characteristics’’ rather than to administration
of PCC.
59 Some studies have indicated a low incidence of
thromboembolic events following administration of PCCs, but
the incidence of such events has appeared to decrease in recent
years. This may be due to newer formulations, which include
the inhibitors of coagulation, such as proteins C, S, and Z, or to
an improved balance of coagulation factors in the concentrate.
60
It appears that the risk of thrombosis is related both to the dose
of PCC administered and to underlying patient
characteristics.
54 Several recent studies
49,50,55,57 have shown a
transient elevation in markers of coagulation activation but no
clinical evidence of thromboembolism with modern PCC
formulations.
ADMINISTRATION OF 3F AND 4F PCC
PCC was originally developed to treat hemophilia B
(Factor IX deﬁciency). Therefore, dosing of PCC is based on
the treatment of this disease: 25 to 50 IU of Factor IX/kg of
body weight.
29,52,61 The ‘‘standard’’ dose of 20 mL/kg, or 500
IU, of PCC is commonly used in the treatment of
overanticoagulation.
54,62 Despite this, newer research indicates
that individualized dosing, based on the body weight of the
patient, their initial INR, and their target INR, may be more
effective than the standard dose at reversing the effect of
warfarin. An open, prospective randomized controlled trial
54
looked at 93 patients who needed acute reversal of their
anticoagulation therapy (47 patients treated with the
standardized dose of PCC and 46 patients treated with an
‘‘individualized’’ dose) and found the individualized group had
89% of patients reach their target INR 15 minutes
posttreatment, compared with only 43% of patients treated with
the standard dose (P , 0.001). Numerous other studies
28,54,61,63
have used ‘‘semi-individualized’’ dosing of PCC (25, 30/35, or
50 IU/kg) based on the patient’s INR at the time of presentation.
PCC, along with FFP, must be administered with 5 to 10 mg
intravenous vitamin K.
16,26,52,54,55
CONCLUSION
Currently there exists no optimal therapy for anticoagulant
overdose. Emergency room physicians are caught balancing the
cost of rFVIIawith the therapeutic delayof FFPand suboptimal
reversal of 3F PCC. 4F PCC, which appears to better meet the
needs of overanticoagulated and bleeding patients, is available
in Europe but not in the United States. Therefore, the authors
recommend the use of 3F PCC with vitamin K and a judicious
amount of rFVIIa or FEIBA to balance timeliness with cost,
especially in patients with critical bleeds, until such time that
4F PCC becomes available in the United States.
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